Education
About Us
Working with TipRanks
Follow Us
Regulus (RGLS)
NASDAQ:RGLS
RGLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.83 - $8.20
Previous CloseN/A
Volume87.19K
Average Volume (3M)2.28M
Market Cap
$544.87M
Enterprise Value$483.08M
Total Cash (Recent Filing)$75.78M
Total Debt (Recent Filing)$274.00K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 12, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding69,234,090
10 Day Avg. Volume1,079,386
30 Day Avg. Volume2,282,964
Financial Highlights & Ratios
PEG Ratio-0.59
Price to Book (P/B)6.75
Price to Sales (P/S)0.00
P/FCF Ratio-12.41
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue387.71
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$8.80Price Target Upside11.82% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
AcquisitionRegulus has entered into an agreement to be acquired by Novartis for an upfront payment plus a contingent value right, significantly exceeding its market cap.
Market PotentialValuation scenario analysis suggests 89-221% potential upside vs. current valuation.
Regulatory ApprovalThere is potential for accelerated regulatory approval, which could lead to earlier financial benefits for Regulus.
Bears Say
Analyst OutlookThe analyst has downgraded Regulus shares to HOLD despite the acquisition announcement, reflecting a more conservative outlook.
Cash OverhangThere is a cash overhang affecting the stock price, which is disconnected from the program's strong fundamentals.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.02% Insiders
9.72% Mutual Funds
25.70% Other Institutional Investors
52.41% Public Companies and Individual Investors
RGLS FAQ
What was Regulus’s price range in the past 12 months?
Regulus lowest stock price was $0.83 and its highest was $8.20 in the past 12 months.
What is Regulus’s market cap?
Regulus’s market cap is $544.87M.
When is Regulus’s upcoming earnings report date?
Regulus’s upcoming earnings report date is Aug 12, 2025 which is in 85 days.
How were Regulus’s earnings last quarter?
Regulus released its earnings results on May 08, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.095.
Is Regulus overvalued?
According to Wall Street analysts Regulus’s price is currently Undervalued.
Does Regulus pay dividends?
Regulus does not currently pay dividends.
What is Regulus’s EPS estimate?
Regulus’s EPS estimate is -0.22.
How many shares outstanding does Regulus have?
Regulus has 69,234,090 shares outstanding.
What happened to Regulus’s price movement after its last earnings report?
Regulus reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went up 0.255%.
Which hedge fund is a major shareholder of Regulus?
Currently, no hedge funds are holding shares in RGLS
---
Regulus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.80 (11.82% Upside)
$8.80 (11.82% Upside)
Blogger Sentiment
Bullish
RGLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $74.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
293.50%
12-Months-Change
Fundamentals
Return on Equity
-53.82%
Trailing 12-Months
Asset Growth
-34.44%
Trailing 12-Months
Company Description
Regulus
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
---
RGLS Stock 12 Month Forecast
Average Price Target
$8.80
▲(11.82% Upside)
Technical Analysis
---